MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This pilot phase I trial compares administration schedules of anti-programmed cell death-1
ligand 1 (PD-L1) monoclonal antibody MPDL3280A and stereotactic ablative radiotherapy in
treating patients with stage IV non-small cell lung cancer. Monoclonal antibodies, such as
anti-PD-L1 monoclonal antibody MPDL3280A, may block tumor growth in different ways by
targeting certain cells. Stereotactic ablative radiotherapy, also known as stereotactic body
radiation therapy, is a specialized radiation therapy that delivers a single, high dose of
radiation directly to the tumor and may kill more tumor cells and cause less damage to normal
tissue. Giving anti-PD-L1 monoclonal antibody MPDL3280A with stereotactic ablative
radiotherapy may be a better treatment for non-small cell lung cancer. However, it is not yet
known what the best administration schedule is for these treatments.